Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

about

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.

P2860

Q30235046-F3DC4F5C-5FA0-4809-A849-1A6B24233E01

P2860

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Item

http://www.wikidata.org/entity/Q36207730

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@ast

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@en

type

Item

label

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@ast

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@en

prefLabel

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@ast

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@en

P1476

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

@en

P2093

Haitao Yang

http://www.w3.org/2001/XMLSchema#string

Heng Lin

http://www.w3.org/2001/XMLSchema#string

Huijuan Chen

http://www.w3.org/2001/XMLSchema#string

Lina Li

http://www.w3.org/2001/XMLSchema#string

Ruifen Shen

http://www.w3.org/2001/XMLSchema#string

Shuimei Luo

http://www.w3.org/2001/XMLSchema#string

Sijing Zhou

http://www.w3.org/2001/XMLSchema#string

Xianhe Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review

Measuring inconsistency in meta-analyses

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Statistical aspects of the analysis of data from retrospective studies of disease

Cancer statistics, 2014

Practical methods for incorporating summary time-to-event data into meta-analysis

Role of angiogenesis in tumor growth and metastasis

P304

1141-1155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.18632/ONCOTARGET.13588

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27901478

http://www.w3.org/2001/XMLSchema#string

P932

5352042

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

about

P2860

P2860

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932